エンドウ　ヤスヒロ   YASUHIRO ENDO   遠藤　康弘    所属   新潟薬科大学  医療技術学部 学部付    職種   准教授
言語種別	英語
発行・発表の年月	2025/06/15
形態種別	論文 - 研究論文（学術雑誌）
査読	査読あり
標題	Roles of HDL function and sphingosine-1-phosphate in vasospastic angina.
執筆形態	単著（従来区分）
掲載誌名	Clinica chimica acta; international journal of clinical chemistry
掲載区分	国外
巻・号・頁	574,pp.120338-120338
担当区分	責任著者
著者・共著者	Kei Sasaki,Hirotaka Ezaki,Yasuhiro Endo,Daisuke Kudo,Yumiko Suenaga,Makoto Ayaori,Masami Sakurada,Katsunori Ikewaki
概要	BACKGROUND: High-density lipoprotein cholesterol (HDL-C) levels are often reduced in patients with vasospastic angina (VSA), but the relevance of HDL functionality to VSA pathogenesis remains unclear. Cholesterol uptake capacity (CUC), a novel cell-free assay reflecting HDL-mediated cholesterol efflux, offers a practical measure of HDL functionality. In parallel, sphingosine-1-phosphate (S1P), an HDL-associated bioactive sphingolipid with vasoprotective properties, may also contribute to VSA. This study aimed to evaluate CUC and vasodilatory HDL components, including S1P, in patients with VSA. METHODS AND RESULTS: Seventy-seven patients, comprising 53 patients who underwent an acetylcholine (Ach) provocation test (32 VSA at diagnosis and 21 non-VSA) and an additional 24 VSA outpatients were included. Patients with VSA had higher triglyceride levels compared with non-VSA patients, but HDL-C levels were not different. Further analysis revealed that CUC was lower in VSA patients at diagnosis compared with non-VSA patients. Serum levels of sphingosine-1-phosphate (S1P), a sphingolipid associated with HDL, were elevated in the VSA group (1.74 ± 0.76 vs. 1.31 ± 0.49 µM; p < 0.01). In the VSA outpatient and Non-VSA groups, S1P levels in crude analysis were significantly associated with VSA (OR = 3.14, 95 % CI: 1.25-7.88, p = 0.01). This association remained significant across all adjusted models (Models 1-4). CONCLUSIONS: The present study found that CUC was a novel indicator of vasospasm-related HDL dysfunctionality and that S1P is a promising biomarker for treated patients with VSA. The cholesterol efflux pathway and sphingolipid metabolism could contribute to the etiology of vasospasm. STUDY REGISTRATION: This clinical study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000020942).
DOI	10.1016/j.cca.2025.120338
PMID	40320159